SOPHiA GENETICS (Nasdaq: SOPH), a prominent player in the healthcare technology sector focusing on data-driven medicine, has unveiled a strategic collaboration with Strand Life Sciences. This partnership aims to introduce groundbreaking solutions to drive the global adoption of precision medicine. By combining the strengths of both entities, the collaboration will grant access to cutting-edge genomics technologies, bioinformatics services, and diagnostic solutions.Headquartered in Bangalore, India, Strand Life Sciences is recognized for its expertise in bioinformatics, laboratory assays, clinical research, and software development.

SOPHiA GENETICS（Nasdaq:SOPH）是专注于数据驱动医学的医疗保健技术领域的杰出参与者，已宣布与Strand Life Sciences进行战略合作。该伙伴关系旨在引入开创性的解决方案，以推动全球采用精准医学。通过结合两个实体的优势，该合作将使人们能够获得尖端的基因组学技术、生物信息学服务和诊断解决方案。Strand Life Sciences总部位于印度班加罗尔，因其在生物信息学、实验室检测、临床研究和软件开发方面的专业知识而受到认可。

Through its tailor-made applications, Strand aids a diverse global clientele, facilitating the expansion and enhancement of precision medicine on a global scale.Ramesh Hariharan, CEO and Co-Founder of Strand, expressed excitement about the collaboration's potential to leverage their collective bioinformatics expertise to elevate patient care globally.The partnership between SOPHiA GENETICS and Strand aims to utilize their bioinformatics capabilities to enhance the accurate analysis of crucial healthcare data and promote data-driven decision-making worldwide.

Strand通过其量身定制的应用程序，帮助多样化的全球客户，促进全球范围内精准医学的扩展和增强。Strand首席执行官兼联合创始人拉梅什·哈里哈兰（RameshHariharan）对该合作有潜力利用其集体生物信息学专业知识来提高全球患者护理水平表示兴奋。SOPHiA GENETICS和Strand之间的合作旨在利用其生物信息学能力来增强对关键医疗保健数据的准确分析，并促进全球范围内的数据驱动决策。

SOPHiA GENETICS will provide support through its decentralized SOPHiA DDM™ Platform, while Strand will contribute its curated variant databases and bioinformatics solutions expertise. Additionally, both companies will collaborate on strategic test co-development initiatives aimed at improving health outcomes in India and beyond.Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS, emphasized the shared vision of both entities to advance patient health outcomes through precision medicine.

SOPHiA GENETICS将通过其分散的SOPHiA DDM™平台提供支持，而Strand将贡献其精选的变异数据库和生物信息学解决方案专业知识。此外，两家公司将合作开展战略测试共同开发计划，旨在改善印度及其他地区的健康状况。SOPHiA GENETICS首席执行官兼联合创始人Jurgi Camblong强调了两家实体通过精准医学促进患者健康的共同愿景。

He stressed the importance of timely and accurate data processing for healthcare organizations to ena.

他强调了及时准确地处理医疗保健组织对ena的重要性。